New DNA technology

Martin Munzer mmunzer at biotech.ufl.org
Mon Jan 12 07:28:16 EST 1998


** Note from the moderator:
**
** I'm told from the person posting this message that this message
** is not meant as an advertising, but presentation of a new 
** technology with the wish of: 
**
** "looking for partners with clinical samples, to do studies with."
**
** With this cleared, I'm passing this along.
**
** regards,  f.                          francis at ncbi.nlm.nih.gov


New DNA technology
The following text is a press release sent out Wednesday through
PRNewswire. Contrary to the hype and hysteria over human cloning, these
technologies will prove of great benefit to mankind and be available
soon.

If this does not interest you, please forward it to someone who might be
interested.

Thanks,

Martin Munzer

PRESS RELEASE

Florida Biotech Companies Fill DNA Technology Gap with New Diagnostic
Technologies

Alachua, Florida, Jan. 7, /PRNewswire/ -- AGENDA, Inc. and CyGene, Inc.,
two Florida based biotech companies, have signed a co-licensing
agreement to market their next-generation DNA diagnostic technologies.
Under the terms of the agreement, AGENDA will market CyGene's patent
pending TPA (TM) technology exclusively, and in conjunction with its own
RFTA (TM) technology.

1997 was an exceptional year for DNA discoveries. Important genetic
sequences, some responsible for diseases such as Alzheimer's, Rheumatoid
Arthritis, Cancers, Heart Disease, etc. were recognized. These were
added to the huge arsenal of already recognized genetic sequences like
HIV, Hepatitis C and numerous contagious or hereditary diseases. One
critical tool missing, which would add to the value of these
discoveries, is a technology that will quickly, reliably and
economically recognize these specific genes when only a few copies are
present.

AGENDA's RFTA (TM) (patent pending) technology complements TPA (TM) in
that both will detect any known genetic sequence while using different
methods. These technologies make early reliable diagnosis of HIV,
Hepatitis C, cancer, parasitic, viral, bacterial and hereditary diseases
a reality. Both processes can be automated, to provide fast and
unprecedented first and second opinions regarding the presence or
absence of the targeted genes. The ability of these technologies to
handle large quantities of DNA or RNA set them apart from other
techniques, which are prone to false results.

For the first time, very early disease recognition (before the onset of
clinical symptoms) is made possible by these next-generation DNA
diagnostic technologies. This will open the door to entirely new
approaches to disease prevention, management and cure. Early stage
diagnosis will make cure scenarios a reality, for many terminal
diseases. First generation DNA technology can only reliably detect HIV,
6-7 months post infection. TPA/RFTA (TM) will be able to detect HIV
accurately shortly after the time of infection.

Similar to computer operating systems, RFTA (TM) and TPA (TM) represent
a technology base from which applications can be developed for
agricultural, veterinary, health sciences, and human diagnostics. Based
on proven molecular biology principles, both technologies can be
configured to complete automation and may be performed in tandem using a
single sample. AGENDA is actively seeking licensees and companies
involved in the design and production of biotech automation equipment.
This is the first public announcement of the existence of TPA (TM) and
RFTA (TM).

Contact:  Martin Munzer, Executive VP, 904-418-1616
 Email mmunzer at dna-diagnostics.com
 http://www.dna-diagnostics.com/ and http://www.cygene.com








More information about the Yeast mailing list